34 results about "Metabolic Inhibition" patented technology

Compositions and methods are provided for the enhanced in vitro synthesis of polypeptides. In order to improve the performance of in vitro protein synthesis reactions, metabolic inhibitors, or manipulation of a source organism, is used to diminish or avoid the action of enzymes responsible for undesirable amino acids production or depletion. A homeostatic system may be used for production of ATP, where the required high energy phosphate bonds are generated in situ, e.g. through coupling with an oxidation reaction. The homeostatic energy source will typically lack high energy phosphate bonds itself, and will therefore utilize free phosphate in the reaction mix during generation of ATP. The homeostatic energy source is provided in combination with an enzyme that catalyzes the creation of high energy phosphate bonds and with an enzyme that can use that high energy phosphate bond to regenerate ATP.

The present invention provides methods for treating a variety of hyperproliferative and inflammatory mucocutaneous disorders, including, basal cell carcinoma, squamous cell carcinoma, psoriasis and atopic dermatitis, as well as skin irritation and disorders associated with skin aging and skin photodamage using inhibitors of cholesterol metabolism. The present invention further relates to the discovery that the combined use of several inhibitors of cholesterol metabolism produces synergistic effects. Furthermore, the present invention is directed to the use of inhibitors of cholesterol metabolism as excipients to enhance the effects of antiinflammatory drugs.

The invention discloses a preservative for fetus free DNA in peripheral blood of pregnant woman and a vacuum blood sampling tube composed of the preservative. The problems of short storage time and easiness in degrading of the fetus free DNA in plasma caused by the shortage of mature collecting and storing technique for the in vitro test of the fetus free DNA in peripheral blood of pregnant woman are solved. The preservative provided by the invention comprises a cell stabilizing agent, an anti-coagulant agent, a buffering solution, a metabolic inhibitor and a DNA enzyme inhibitor. The preservative can stabilize the karyocyte of the peripheral blood of pregnant woman, can prevent the cell chromosome DNA from being released, can restrain DNA enzyme degradation and is beneficial to the stability of fetus free DNA.

The invention relates to the field of biology and provides a method for performing mixed fermentation on lactobacillus acidophilus and clostridium butyricum. The method comprises the following steps:inoculating the lactobacillus acidophilus on an unsterilized solid culture medium to perform fermentation, and then inoculating clostridium butyricum liquid to perform fermentation. The synergistic inhibition effect on infectious microbes by the lactobacillus acidophilus and the clostridium butyricum can be utilized, the growth of the infectious microbes can be effectively inhibited and the infectious microbes in the production process can be effectively controlled; furthermore, under the condition of not sterilizing the raw materials, the lactobacillus acidophilus and the clostridium butyricum are fermented, so that the cost is reduced and the practicability is high. In addition, the invention also provides fermentation equipment. The fermentation equipment can be applied to solid fermentation production of anaerobic bacteria or facultative anaerobic bacteria such as the clostridium butyricum and the lactobacillus acidophilus; and the fermentation equipment discharges volatile metabolic products such as hydrogen and carbon dioxide to the external air through a gas outlet pipe, relieves metabolic inhibition, and can release viable bacteria to improve the growth and reproduction capacity and increase the number of the fermented viable bacteria.

Disclosed is a method for promoting auto-induction of transcription of cloned DNA in cultures of bacterial cells grown batchwise, the transcription being under the control of a promoter whose activity can be induced by an exogenous inducer whose ability to induce said promoter is dependent on the metabolic state of said bacterial cells. Initially, a culture media is provided which includes: i) an inducer that causes induction of transcription from said promoter in said bacterial cells; and ii) a metabolite that prevents induction by said inducer, the concentration of said metabolite being adjusted so as to substantially preclude induction by said inducer in the early stages of growth of the bacterial culture; but such that said metabolite is depleted to a level that allows induction by said inducer at a later stage of growth. The culture medium is inoculated with a bacterial inoculum, the inoculum comprising bacterial cells containing cloned DNA, the transcription of which is induced by said inducer. The culture is then incubated under conditions appropriate for growth of the bacterial cells. Also disclosed is a method for improving the production of a selenomethionine-containing protein or polypeptide in a bacterial cell, the protein or polypeptide being produced by recombinant DNA techniques, the bacterial cell encoding a vitamin B12-dependent homocysteine methylase. The method for improving the production of this protein or polypeptide includes culturing the bacterial cell in a culture medium containing vitamin B12. Finally, disclosed is a method for suppressing transcription of cloned DNA in cultures of bacterial cells grown batchwise, said transcription being under the control of a promoter whose activity can be induced by an exogenous inducer whose ability to induce said promoter is dependent on the metabolic state of said bacterial cells. This aspect includes the steps of: a) providing a culture medium comprising a carbon source whose uptake and metabolism by said bacterial cells suppresses induction of transcription from said promoter; b) inoculating the culture medium with a bacterial inoculum, the inoculum comprising bacterial cells containing cloned DNA, the transcription of which is suppressed by the carbon source; and c) incubating the culture of step b), with shaking, under conditions appropriate for growth of the bacterial cells.

The invention provides a composition and method for preserving nucleic acid in urine. The composition provided by the invention contains the following components in percentage by weight: 2%-20% of a preservative, 1%-10% of a quenching agent, 2%-40% of a nuclease inhibitor, 5%-60% of a hydrophilic polymer, 1%-30% of a penetrating agent and 0.01%-10% of a metabolic inhibitor. The composition is capable of improving the stability of free nucleic acids in a biological sample and preventing release of nucleic acids in a karyocyte genome, and the separated free nucleic acids are widely suitable formass clinical diagnosis, development and application.

The present disclosure provides pharmaceutical compositions, combinations, and uses thereof for treating and/or preventing cancer. For example, a pharmaceutical composition of the present disclosure can also include 2-acetylnaphtho[2,3-b]furan-4,9-dione, a prodrug thereof, a pharmaceutically acceptable salt of any of the foregoing, or a pharmaceutically acceptable solvate of any of the foregoing; and at least one excipient independently being a binder, a disintegrant, a lubricant, a surfactant, one other excipient, or a combination thereof. For example, a combination of the present disclosure can include 2-acetylnaphtho[2,3 b]furan-4,9-dione, a prodrug thereof, a pharmaceutically acceptable salt of any of the foregoing, or a pharmaceutically acceptable solvate of any of the foregoing; and at least one second agent independently being; a metabolic inhibitor, a transporter inhibitor, a NSAID, or a combination thereof.

The present invention provides, in some embodiments, methods of promoting an immune response in a subject in need thereof, comprising administering to a subject a population of immune cells that express an exogenous enzyme that facilitates immune cell function in a nutrient-poor environment. Other embodiments of the invention include methods of promoting an immune response to a tumor in a subject in need thereof, comprising administering to the subject an effective amount of an agent that provides a one-carbon unit (e.g., formate) and an agent that promotes an anti-tumor response, and methods of promoting an immune response to a tumor in a subject in need thereof, comprising administering to a subject an effective amount of an agent that inhibits consumption of metabolic fuels by tumor cells. The invention also provides, in other embodiments, compositions comprising an ex vivo population of immune cells expressing an exogenous enzyme that enhances immune cell function in nutrient poor environments, and compositions comprising a nucleic acid expression construct encoding an inhibitor of glucose metabolism, and a pharmaceutically acceptable carrier or excipient.

Methods, compositions and compounds that include a nucleic acid comprising a sequence consisting essentially of polyT/polyU and an agent that inhibits the production or activity of an immunosuppressive compound for treating tumors are described.

The invention relates to a coronavirus sample preservation solution and application thereof. The coronavirus sample preservation solution comprises a cell preserving fluid, a cell membrane protective agent, an RNA enzyme inhibitor, a virus metabolism inhibitor, a virus inactivator and a bacteriostatic agent, wherein the virus inactivator is sodium caprylate, and the bacteriostatic agent is Funme polypeptide. The bacteriostatic agent in the preservation solution selects biological Funme polypeptide, growth of various microorganisms can be inhibited in a broad spectrum, nucleic acid detection of coronaviruses is not interfered, the selected virus inactivator does not influence detection of new coronavirus amplification reagents produced by any manufacturer, and RNA in a sample cannot be degraded by RNA enzyme in the preservation and transportation process through the RNA enzyme inhibitor. According to the preservation solution, collected coronavirus samples are comprehensively protected from all links, the samples are kept in an original state in the preservation and transportation process, the originality of the samples can still be kept after the samples are preserved for 5 days at the temperature of 2-8 DEG C, and detection results consistent with those of the original samples are obtained.

The invention discloses a kit for tigecycline drug sensitivity detection and a method for tigecycline drug sensitivity detection by using the same. The kit comprises a tigecycline drug sensitive plate and incubation liquid. The tigecycline drug sensitive plate comprises a drug sensitive plate body, and the plate holes of the drug sensitive plate body are coated with tigecycline powder. The tigecycline drug sensitivity detection method comprises the following steps of: inoculating a to-be-detected strain suspension into a tigecycline drug sensitivity plate, incubating, adding heavy water into the tigecycline drug sensitivity plate, continuing to incubate for a period of time, sampling at different time points, and carrying out Raman detection; calculating data in a spectrum obtained by Raman detection of the sample to obtain the minimum inhibitory concentration eMIC-MA in the drug concentration under the condition that the metabolic inhibition level of the sample is greater than or equal to 0.8 after continuous incubation for a period of time; and judging the drug sensitivity of the to-be-detected strain tigecycline according to a result judgment standard formulated by the American Food and Drug Administration and the European Drug Sensitivity Test Committee according to the numerical value of eMIC-MA. According to the method, the tigecycline drug sensitivity result can be quickly and accurately obtained.

Presented herein are methods for the treatment of oncological disorders by the co-administration of CoQ10 compositions and at least one fatty acid metabolism inhibitor. In one embodiment, the CoQ10 compositions are lipid-containing compositions. The fatty acid metabolism inhibitor may be an inhibitor of fatty acid synthesis, storage, transport or degradation. The fatty acid metabolism inhibitor may also be a modulator of fatty acid structure, for example a fatty acid desaturase or elongase. The fatty acid inhibitor may inhibit any molecule involved in fatty acid metabolism, such as fatty acid synthase (FASN), carnitine palmitoyltransferase 1 (CPT-1), long-chain 3-ketoacyl-CoA thiolase, or stearoyl-CoA desaturase-1 (SCD-1). In embodiments, the fatty acid metabolism inhibitor may be C75, Etomoxir, trimetazidine or A939572.

The invention relates to application of CAI (Carboxyamidotriazole) and glutamate uptake and metabolic inhibitors in resisting tumor. Specifically, the invention relates to the application of the CAI and a combination of one or multiple glutamate uptake and metabolic inhibitors in preparing an anti-tumor drug for mammals. Particularly, the invention relates to the application of the CAI and a combination of an amino acid transporter inhibitor, a glutamate dehydrogenase 1 inhibitor and a glutaminase inhibitor in preparing the anti-tumor drug for the mammals.

The present disclosure relates to compounds that are capable of penetrating the blood brain barrier to modulate the activity of EGFR tyrosine kinase. The disclosure further relates to methods of treating glioblastoma and other EGFR-mediated cancers, such as those that have been determined to have altered glucose metabolism in the presence of inhibitors. The present disclosure also provides methods of administering to a subject a glucose metabolism inhibitor and a cytoplasmic p53 stabilizer.

The invention relates to a genetically engineered bacterium for producing L-methionine at high yield as well as a construction method and application of the genetically engineered bacterium. According to the invention, an L-methionine synthesis network of escherichia coli is modified, and the utilization capacity of escherichia coli on methylenetetrahydrofolic acid is enhanced by enhancing metF and GCV in a carbon module of an escherichia coli-L-methionine synthesis pathway; by replacing original promoters of fliY and malY with a Trc promoter derived from pTrc99A, a cysteine/cystine internal transport pathway and a cysteine utilization pathway are enhanced, and metabolic inhibition of escherichia coli caused by cysteine generation is relieved; and by knocking out glyA of escherichia coli and introducing glyA derived from Arthrobacter sp.FB24 for overexpression on plasmids, limitation of serine hydroxymethyltransferase of large intestines is relieved, finally, high-yield bacterium containing plasmids is obtained, and the yield of L-methionine is increased to 3.83 g/L from 2.8 g/L.